High
37.980
Open
37.740
VWAP
36.90
Vol
10.60M
Mkt Cap
150.71B
Low
36.270
Amount
391.33M
EV/EBITDA(TTM)
6.77
Total Shares
2.04B
EV
72.87B
EV/OCF(TTM)
11.99
P/S(TTM)
1.98
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas...Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2025Q2
FY2025Q3
7.47B
+1.43%
0.984
-8.57%
8.01B
+1.64%
1.050
-5.79%
8.40B
+4.85%
1.203
-6.96%
Estimates Revision
The market is revisingUpwardthe revenue expectations for GSK plc (GSK) for FY2025, with the revenue forecasts being adjusted by 1.78%over the past three months. During the same period, the stock price has changed by7.57%.
Revenue Estimates for FY2025
Revise Upward

+1.78%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+3.16%
In Past 3 Month
Stock Price
Go Up

+7.57%
In Past 3 Month
2 Analyst Rating

16.34% Upside
Wall Street analysts forecast GSK stock price to riseover the next 12 months. According to Wall Street analysts, the average 1-year price target for GSK is 42.50USD with a low forecast of40.00USD and a high forecast of45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
2 Hold
0 Sell
Hold

16.34% Upside
Current: 36.530

Low
40.00
Averages
42.50
High
45.00
Jefferies
Peter Welford
Strong Buy
to
Hold
Downgrades
n/a
2024-11-12
Reason
Jefferies analyst Peter Welford downgraded GSK to Hold from Buy with a price target of $39.50, down from $53. The firm finds it "frustrating" that despite the favorable Zantac settlement, robust performance of GSK's Specialty unit, and pipeline successes, the shares "continue to languish." While GSK's fundamental value remains compelling, overhangs for the company's Arexvy and Shingrix vaccines, "more subdued" 2025 growth, and few near-term catalysts to "rebuild belief" suggests the stock's value disconnect may persist, the analyst tells investors in a research note.
Guggenheim
Seamus Fernandez
Strong Buy
to
Hold
Downgrades
n/a
2024-10-31
Reason
Guggenheim analyst Seamus Fernandez downgraded GSK to Neutral from Buy without a price target following the Q3 report. While the company's guidance appears achievable and it is a "reasonable defensive pharma to own" with a low multiple and solid dividend, limited upside in pipeline catalysts and 2025 estimates "makes it increasingly challenging for us to recommend that investors put new money to work in GSK until pipeline visibility improves materially," the analyst tells investors in a research note.
UBS
Jo Walton
Strong Buy
to
Hold
Downgrades
n/a
2024-07-08
Reason
Jefferies
Peter Welford
Strong Buy
Maintains
$53 → $53
2024-07-02
Reason
Goldman Sachs
Rajan Sharma
Hold
Initiates
$47
2024-05-30
Reason
Valuation Metrics
The current forward P/E ratio for GSK plc(GSK.N) is 0.08, compared to its 5-year average forward P/E of 11.15. For a more detailed relative valuation and DCF analysis to assess GSK plc 's fair value, click here.
Forward PE

Strongly Undervalued
5Y Average PE
11.15
Current PE
0.08
Overvalued PE
14.04
Undervalued PE
8.26
Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
8.57
Current EV/EBITDA
6.53
Overvalued EV/EBITDA
10.38
Undervalued EV/EBITDA
6.77
Forward PS

Fair
5Y Average PS
2.11
Current PS
1.81
Overvalued PS
2.44
Undervalued PS
1.78
Financials
Annual
Quarterly
FY2024Q4
YoY :
+4.04%
10.40B
Total Revenue
FY2024Q4
YoY :
-8.06%
1.14B
Operating Profit
FY2024Q4
YoY :
+29.59%
641.87M
Net Income after Tax
FY2024Q4
YoY :
+18.18%
0.13
EPS - Diluted
FY2024Q4
YoY :
-52.90%
1.27B
Free Cash Flow
FY2024Q4
YoY :
-2.96%
68.93
Gross Profit Margin - %
FY2024Q4
YoY :
-25.13%
9.86
FCF Margin - %
FY2024Q4
YoY :
+24.90%
6.17
Net Margin - %
FY2024Q4
YoY :
-42.55%
10.45
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
16.5M
USD
Months
6-9
1
22.3M
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
2.8M
Volume
1
3-6
Months
15.3M
Volume
15
6-9
Months
3.4M
Volume
15
0-12
Months
13.5M
Volume
26
Bought
0-3
2
12.7M
Volume
Months
3-6
12
6.5M
Volume
Months
6-9
11
5.8M
Volume
Months
0-12
21
3.7M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
8.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
GSK News & Events
Events Timeline
2025-04-05 (ET)
News
9.0
04-03BenzingaPinnedNew Study Shows Shingles Vaccine Linked To 20% Lower Dementia Risk, GSK Stock Pops
7.0
04-04PRnewswirePinnedContact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against GSK plc(GSK)
8.0
04-04SeekingAlphaEuropean pharma evaluates ways to mitigate impact of tariff uncertainty
7.0
04-04SeekingAlphaPfizer, GSK settle patent lawsuit over RSV vaccines
7.0
04-03GlobenewswireGSK plc Investors: Please contact the Portnoy Law Firm to recover your losses; April 7, 2025 Deadline to file Lead Plaintiff Motion
7.0
04-03PRnewswireShareholders that lost money on GSK plc(GSK) should contact The Gross Law Firm about pending Class Action - GSK
7.0
04-03GlobenewswireDeadline Alert: GSK plc. (GSK) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
7.0
04-03GlobenewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
7.0
04-02PRnewswireGSK Deadline: GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit
9.0
04-02SeekingAlphaShingles vaccine can cut risk of developing dementia - study
7.0
04-02GlobenewswireGSK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GSK plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
7.0
04-02Globenewswireהתראת מועד אחרון לתביעה נגד GSK: רוזן, משרד עורכי דין מדורג ומוביל, מעודד את משקיעי GSK plc עם הפסדים של יותר מ-100 אלף דולר להבטיח ייעוץ לפני המועד האחרון החשוב של 7 באפריל בתביעה ייצוגית בניירות ערך – GSK
7.0
04-02GlobenewswireGSK DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages GSK plc Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action – GSK
7.0
04-02GlobenewswireONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GSK
8.0
04-01CNBCTrump's tariffs are a new challenge for Big Pharma. Here are the best-positioned stocks
7.0
04-01PRnewswireShareholders of GSK plc Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK
7.0
04-01GlobenewswireGSK plc Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights – GSK
7.0
03-31PRnewswireClass Action Filed Against GSK plc (GSK) Seeking Recovery for Investors - Contact The Gross Law Firm
7.0
03-31GlobenewswireShareholders of GSK plc Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights – GSK
7.0
03-31GlobenewswireDEADLINE ALERT for MPWR, GSK, and ICLR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
People Also Watch

PENG
Penguin Solutions Inc
15.190
USD
-6.18%

PDM
Piedmont Office Realty Trust Inc
6.680
USD
-3.47%

STAA
STAAR Surgical Co
15.920
USD
-8.51%

EMBC
Embecta Corp
12.000
USD
-2.99%

PSFE
Paysafe Ltd
14.160
USD
-5.35%

CCEC
Capital Clean Energy Carriers Corp
18.230
USD
-7.93%

ARRY
Array Technologies Inc
4.390
USD
-0.90%

NG
NovaGold Resources Inc
2.610
USD
-8.10%

PEBO
Peoples Bancorp Inc
27.280
USD
-0.98%

AMSC
American Superconductor Corp
15.800
USD
-5.22%
FAQ

What is GSK plc (GSK) stock price today?
The current price of GSK is 36.53 USD — it hasdecreased-6.36 % in the last trading day.

What is GSK plc (GSK)'s business?

What is the price predicton of GSK Stock?

What is GSK plc (GSK)'s revenue for the last quarter?

What is GSK plc (GSK)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for GSK plc (GSK)'s fundamentals?

How many employees does GSK plc (GSK). have?
